An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, Hiroshi Tanabe, Kazuyoshi Kato, Hiroaki Itamochi, Hiroyuki Fujiwara, Shoji Kamiura, Tetsutaro Hamano and Toru Sugiyama Tags: Study protocol Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Fallopian Tube Cancer | Japan Health | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study